medical research 7 ©Belova59 – pixabay.com Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported first-quarter results that exceeded expectations, supported by strong growth from its collaboration with Sanofi on Dupixent. Adjusted earnings per share came in at $9.47, ahead of the analyst consensus of $8.97 by $0.50. Revenue reached $3.6 billion, up 19% year over year from $3.0 billion and above the $3.48 billion estimate. Shares rose 1.4% following the announcement. Global net sales of Dupixent, record ...